Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2006

View Archived Issues

Bryostatin 1 provides protection against ischemia/reperfusion injury

Orally available novel nucleotide is active against drug-resistant HIV-1 mutants

Updated profile of ARD-353, a cardioprotective nonpeptide delta opioid receptor agonist

Tadalafil improves neurological function in a preclinical stroke model

Initial preclinical data for ReN-004 stem cell lines for Parkinson's disease

Three registrational phase III trials of Erbitux complete enrollment

New phase III trial studies Nexavar in NSCLC

17beta-Estradiol targets STAT3 to provide neuroprotection following stroke

Dana-Farber Cancer Institute to study CTCE-9908 for brain cancer

BioInvent reassigns rights to develop osteoarthritis drugs to Cartela

CFFT to continue support for Copernicus' gene therapy for cystic fibrosis

New studies suggest Ampligen and Alferon may protect against avian flu

NNZ-4921 shows promise in rat peripheral neuropathy model

Results of studies investigating AAGP effect on cellular growth and function

Orphan drug designation for Coramsine for melanoma

Targeting gamma-secretase provides neuroprotection in preclinical stroke

Novel compounds with possible utility in the treatment of cancer revealed

Preclinical and clinical data on JTK-303/GS-9137 disclosed

New therapeutic agents for acne disclosed in recent Galderma patent

Rho kinase inhibitors prepared and tested at GlaxoSmithKline

CD38-derived peptide shows potent anti-HIV-1 activity in vitro

New HIV protease inhibitor shows promise for multidrug-resistant HIV infection

Pilot bioavailability testing of CDT extended release ondansetron tablets

Vusion approved for treatment of diaper dermatitis complicated by candidiasis

Hycamtin sNDA accepted for priority review

Rimonabant receives approvable, nonapprovable letters

FDA approval for new oral contraceptive Loestrin 24 Fe

CE Mark for CoStar paclitaxel-eluting stent

Alvesco approved in Europe for mild to severe persistent asthma in adolescents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...